The original Signal Transduction (ST) Program Area was established in 1997 to bring together researchers Studying a variety of signaling pathways, including pathways initiated by receptors and membrane-mediated events, heterotrimeric G-protein, small G-protein- and protein kinase-mediated intermediate signaling events, and distal transcription factor activation. The ST Program Area sponsored large symposia to promote discussion and to facilitate interaction among ST researchers. Research during this period led to the identification of molecular targets, which then led to the development of signal transduction inhibitors. Because of the translational potential of signal transduction research for cancer therapy, we wanted to create a platform where basic scientists could discuss their studies on signaling pathways with clinicians carrying out clinical trials of signal transduction inhibitors. To create this platform, the ST Program Area was reconfigured in 2007 as the Signal Transduction and Therapeutics (STT) Program Area. The new/revised STT Program Area includes both basic scientists and clinicians.
Our aim i s to have an easy, transparent transition from basic science to the clinic and from the clinic to basic science. During the current funding period, basic science and clinical activities in the STT Program Area have truly become integrated. Our members share a passion to promote new cancer therapies based on basic signal transduction observations. We promote translational aspects of our Program Area by holding meetings and seminars that gather basic scientists and clinicians, who exchange their experience and knowledge on signaling pathways of common interest. The STT Program Area is comprised of 47 members, including four
): Most targeted cancer therapeutics that have been developed to date inhibit specific signaling pathways required for the growth of cancer cells. The Signal Transduction and Therapeutics Program Area brings together basic, translational, and clinical researchers to optimize and speed the development of novel therapeutics that target signaling pathways.
|Li, Gang; Lu, Xuyang (2015) A Bayesian approach for instrumental variable analysis with censored time-to-event outcome. Stat Med 34:664-84|
|Epeldegui, Marta; Blom, Bianca; Uittenbogaart, Christel H (2015) BST2/Tetherin is constitutively expressed on human thymocytes with the phenotype and function of Treg cells. Eur J Immunol 45:728-37|
|Bower, Julienne E; Crosswell, Alexandra D; Stanton, Annette L et al. (2015) Mindfulness meditation for younger breast cancer survivors: a randomized controlled trial. Cancer 121:1231-40|
|Arensman, Michael D; Telesca, Donatello; Lay, Anna R et al. (2014) The CREB-binding protein inhibitor ICG-001 suppresses pancreatic cancer growth. Mol Cancer Ther 13:2303-14|
|Li, Keyu; Tavaré, Richard; Zettlitz, Kirstin A et al. (2014) Anti-MET immunoPET for non-small cell lung cancer using novel fully human antibody fragments. Mol Cancer Ther 13:2607-17|
|Ke, Ruian; Loverdo, Claude; Qi, Hangfei et al. (2014) Modelling clinical data shows active tissue concentration of daclatasvir is 10-fold lower than its plasma concentration. J Antimicrob Chemother 69:724-7|
|Fu, Maoyong; Maresh, Erin L; Helguera, Gustavo F et al. (2014) Rationale and preclinical efficacy of a novel anti-EMP2 antibody for the treatment of invasive breast cancer. Mol Cancer Ther 13:902-15|
|Leoh, Lai Sum; Morizono, Kouki; Kershaw, Kathleen M et al. (2014) Gene delivery in malignant B cells using the combination of lentiviruses conjugated to anti-transferrin receptor antibodies and an immunoglobulin promoter. J Gene Med 16:11-27|
|Tong, Maomeng; McHardy, Ian; Ruegger, Paul et al. (2014) Reprograming of gut microbiome energy metabolism by the FUT2 Crohn's disease risk polymorphism. ISME J 8:2193-206|
|De Azambuja, Katherine; Barman, Provabati; Toyama, Joy et al. (2014) Validation of an HPV16-mediated carcinogenesis mouse model. In Vivo 28:761-7|
Showing the most recent 10 out of 192 publications